Investigating the Effectiveness of Melatonin in the Treatment of Critically Ill Patients with COVID-19 Hospitalized in the Intensive Care Unit: A Double-Blind Randomized Clinical Trial.

Q2 Medicine
Medical Journal of the Islamic Republic of Iran Pub Date : 2024-04-15 eCollection Date: 2024-01-01 DOI:10.47176/mjiri.38.41
Atefe Tirkan, Delaram Eskandari, Maryam Roham, Oldooz Aloosh, Tayeb Ramim, Hale Afshar
{"title":"Investigating the Effectiveness of Melatonin in the Treatment of Critically Ill Patients with COVID-19 Hospitalized in the Intensive Care Unit: A Double-Blind Randomized Clinical Trial.","authors":"Atefe Tirkan, Delaram Eskandari, Maryam Roham, Oldooz Aloosh, Tayeb Ramim, Hale Afshar","doi":"10.47176/mjiri.38.41","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Melatonin, a tryptophan product, has anti-inflammatory and virucidal effects. A study evaluated whether melatonin is more effective than placebo in critically ill COVID-19 patients.</p><p><strong>Methods: </strong>The present study used a double-blind, randomized clinical trial in patients with COVID-19 hospitalized in the intensive care unit of Rasool Akram Hospital, Tehran. Iran. Melatonin 10 mg and placebo were given to the patients at night before bed. Patients were randomly divided into 2 groups. The first group was given melatonin with a therapeutic dose of 10 mg daily, and the second group was given a placebo with the same dose of 10 mg daily. Patients received melatonin or placebo for 7 days.The chi-square or Fisher exact test was used to compare qualitative variables. The study analyzed the mean of the variables under investigation by conducting a 2-factor repeated measures analysis of variance at 3 different time intervals in those administered medication or placebo.</p><p><strong>Results: </strong>The study analyzed 44 melatonin patients and 42 placebo groups. The mean intensive care unit (ICU) hospitalization days were 11.23 ± 4.73 days in the melatonin group and 11.90 ± 6.52 days in the placebo group (<i>P</i> = 0.582). The mean days of hospitalization in the melatonin group were 19.70 ± 8.77 days and 21.48 ± 10.85 days in the placebo group (<i>P</i> = 0.407). The mean oxygen saturation before and after discharge from ICU in the melatonin group was 81 ± 6.73%, 91.02 ± 1.17%, and in the placebo group, 83.36 ± 8.27%, 91.21 ± 1.26, respectively (<i>P</i> = 0.467 and <i>P</i> = 0.150).</p><p><strong>Conclusion: </strong>Melatonin can significantly reduce inflammation and oxidative stress markers in patients, making it a promising therapeutic option for COVID-19 patients. Further research is needed to determine the optimal treatment dosage and duration. Nonetheless, these results offer a promising avenue for future research and clinical practice.</p>","PeriodicalId":18361,"journal":{"name":"Medical Journal of the Islamic Republic of Iran","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480672/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Journal of the Islamic Republic of Iran","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47176/mjiri.38.41","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Melatonin, a tryptophan product, has anti-inflammatory and virucidal effects. A study evaluated whether melatonin is more effective than placebo in critically ill COVID-19 patients.

Methods: The present study used a double-blind, randomized clinical trial in patients with COVID-19 hospitalized in the intensive care unit of Rasool Akram Hospital, Tehran. Iran. Melatonin 10 mg and placebo were given to the patients at night before bed. Patients were randomly divided into 2 groups. The first group was given melatonin with a therapeutic dose of 10 mg daily, and the second group was given a placebo with the same dose of 10 mg daily. Patients received melatonin or placebo for 7 days.The chi-square or Fisher exact test was used to compare qualitative variables. The study analyzed the mean of the variables under investigation by conducting a 2-factor repeated measures analysis of variance at 3 different time intervals in those administered medication or placebo.

Results: The study analyzed 44 melatonin patients and 42 placebo groups. The mean intensive care unit (ICU) hospitalization days were 11.23 ± 4.73 days in the melatonin group and 11.90 ± 6.52 days in the placebo group (P = 0.582). The mean days of hospitalization in the melatonin group were 19.70 ± 8.77 days and 21.48 ± 10.85 days in the placebo group (P = 0.407). The mean oxygen saturation before and after discharge from ICU in the melatonin group was 81 ± 6.73%, 91.02 ± 1.17%, and in the placebo group, 83.36 ± 8.27%, 91.21 ± 1.26, respectively (P = 0.467 and P = 0.150).

Conclusion: Melatonin can significantly reduce inflammation and oxidative stress markers in patients, making it a promising therapeutic option for COVID-19 patients. Further research is needed to determine the optimal treatment dosage and duration. Nonetheless, these results offer a promising avenue for future research and clinical practice.

研究褪黑素治疗重症监护病房 COVID-19 重症患者的效果:双盲随机临床试验。
背景:褪黑素是一种色氨酸产品,具有抗炎和杀病毒作用。一项研究评估了褪黑素对 COVID-19 重症患者是否比安慰剂更有效:本研究对德黑兰 Rasool Akram 医院重症监护室住院的 COVID-19 患者进行了双盲随机临床试验。伊朗。患者每晚睡前服用 10 毫克褪黑素和安慰剂。患者被随机分为两组。第一组每天服用 10 毫克治疗剂量的褪黑素,第二组每天服用 10 毫克相同剂量的安慰剂。患者接受褪黑素或安慰剂治疗 7 天。定性变量的比较采用卡方检验或费雪精确检验。该研究通过对服用药物或安慰剂的患者进行3个不同时间间隔的2因素重复测量方差分析,分析了所研究变量的平均值:研究分析了 44 位褪黑素患者和 42 位安慰剂组患者。褪黑素组的平均重症监护室(ICU)住院天数为(11.23 ± 4.73)天,安慰剂组为(11.90 ± 6.52)天(P = 0.582)。褪黑素组的平均住院日为(19.70 ± 8.77)天,安慰剂组为(21.48 ± 10.85)天(P = 0.407)。褪黑素组ICU出院前后的平均血氧饱和度分别为81±6.73%、91.02±1.17%,安慰剂组分别为83.36±8.27%、91.21±1.26(P = 0.467和P = 0.150):褪黑素能明显降低患者的炎症和氧化应激指标,因此是COVID-19患者的一种很有前景的治疗选择。确定最佳治疗剂量和持续时间还需要进一步研究。不过,这些结果为未来的研究和临床实践提供了一个很有前景的途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.40
自引率
0.00%
发文量
90
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信